Abstract
PURPOSE: To determine the frequency of and reasons for treatment changes in patients with psoriasis.
MATERIALS AND METHODS: A retrospective chart review of 140 patients with psoriasis treated with adalimumab or etanercept seen at Kaiser Permanente Los Angeles Medical Center between September 20, 2004 and September 8, 2017 was conducted. The first treatment change and reason for that change was documented.
RESULTS: Of 140 patients, 103 patients had treatment changes, most commonly due to inefficacy, however complicating events and changes due to patient preference were also seen.
CONCLUSION: Although biologics are considered the gold standard for psoriasis, clinicians should still take individual variations in response and preferences into account.
| Original language | English |
|---|---|
| Journal | The Journal of dermatological treatment |
| Pages (from-to) | 1-6 |
| Number of pages | 6 |
| ISSN | 0954-6634 |
| DOIs | |
| Publication status | Published - 15 Feb 2018 |
Keywords
- Journal Article